BG Lab shared a post on X:
“We (BG Lab) had a very productive August. Please tag along for an update on the major accomplishments from our team in August.
Our visiting colleague Laure-Anne Teuwen published an editorial in JNCI about clinical versus statistical significance.
Title: Success in oncology phase 3 trials: a small P value or patient value
Authors: Laure-Anne Teuwen, Gregory R Pond, Bishal Gyawali
Read the Full Article.
Our Common Sense Oncology fellow Samuel Stevens published a commentary in ACS Journal Cancer highlighting the need for precision in dosing, endpoints and trial reporting in the context of codebreak 300 trial.
Title: CodeBreaK or code blue? Assessing sotorasib’s vital signs in metastatic colorectal cancer
Authors: Samuel X. Stevens, M Bioethics, Bishal Gyawali
Read the Full Article.
Our visiting colleague Laure-Anne Teuwen published another editorial in BMJ Oncology discussing the control arms in clinical trials run in LMICs.
Title: Inferior control arms in oncology trials in LMICs: contextualised or compromised?
Authors: Laure-Anne Teuwen, Bishal Gyawali
Read the Full Article.
Our team leader Bishal Gyawali discussed the intersection of CSO and precision oncology in this piece published in Marathon of Hope Cancer Centres Network.
More posts featuring Bishal Gyawali on OncoDaily.